Skip to main content

fludrocortisone

Generic: FLUDROCORTISONE ACETATE·Brand: FLORINEF, FLUDROCORTISONE ACETATE

fludrocortisone: 5 clinical trials tracked.

fludrocortisone evidence translation

What we can confirm

5 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about fludrocortisone, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trials (5)

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-5684 in Healthy Adult Male Participants

NCT07548606·Phase 1
Completed

Primary endpoint: Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of opevesostat

Interventionalopen14 enrolledStarted 2026-05Completion 2026-061 site · United StatesMerck Sharp & Dohme LLC

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

NCT06979596·Phase 2
Recruiting

Primary endpoint: Progression-Free Survival (PFS) - All Cohorts

InterventionalRandomizedsingle250 targetStarted 2025-08Completion 2027-1150 sites · Argentina, Brazil, Canada, Chile…Merck Sharp & Dohme LLC

A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06136598·Phase 1·MRK
Active, not recruiting

Primary endpoint: Number of Participants Who Experience an Adverse Event (AE)

Interventionalopen14 targetStarted 2024-01Completion 2026-033 sites · ChinaMerck Sharp & Dohme LLC

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

NCT06136624·Phase 3
Recruiting

Primary endpoint: Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants

InterventionalRandomizedopen1,310 targetStarted 2023-12Completion 2030-0250 sites · Argentina, United StatesMerck Sharp & Dohme LLC

MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)

NCT06136650·Phase 3
Recruiting

Primary endpoint: Radiographic Progression-Free Survival (rPFS)

InterventionalRandomizedopen1,314 targetStarted 2023-12Completion 2030-1250 sites · United StatesMerck Sharp & Dohme LLC